{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:35:21Z","timestamp":1789878921981,"version":"4.0.1"},"reference-count":62,"publisher":"American Chemical Society (ACS)","issue":"6","license":[{"start":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T00:00:00Z","timestamp":1520294400000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccby_termsofuse.html"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP40827"],"award-info":[{"award-number":["OPP40827"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP48262"],"award-info":[{"award-number":["OPP48262"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004409","name":"Doctors Without Borders","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000278","name":"Department for International Development","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100000278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f?r Bildung und Forschung","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007729","name":"Ministerie van Buitenlandse Zaken","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100007729","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Discovery of the potent antileishmanial effects of antitubercular 6-nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles and 7-substituted 2-nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines stimulated the examination of further scaffolds (e.g., 2-nitro-5,6,7,8-tetrahydroimidazo[2,1-b][1,3]oxazepines), but the results for these seemed less attractive. Following the screening of a 900-compound pretomanid analogue library, several hits with more suitable potency, solubility, and microsomal stability were identified, and the superior efficacy of newly synthesized 6R enantiomers with phenylpyridine-based side chains was established through head-to-head assessments in a Leishmania donovani mouse model. Two such leads (R-84 and R-89) displayed promising activity in the more stringent Leishmania infantum hamster model but were unexpectedly found to be potent inhibitors of hERG. An extensive structure\u2013activity relationship investigation pinpointed two compounds (R-6 and pyridine R-136) with better solubility and pharmacokinetic properties that also provided excellent oral efficacy in the same hamster model (&amp;gt;97% parasite clearance at 25 mg\/kg, twice daily) and exhibited minimal hERG inhibition. Additional profiling earmarked R-6 as the favored backup development candidate.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.7b01581","type":"journal-article","created":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T13:56:16Z","timestamp":1519134976000},"page":"2329-2352","source":"Crossref","is-referenced-by-count":54,"title":["Development of\n(6\n                    <i>R<\/i>\n                    )-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5\n                    <i>H<\/i>\n                    -imidazo[2,1-\n                    <i>b<\/i>\n                    ][1,3]oxazine\n(DNDI-8219): A New Lead for Visceral Leishmaniasis"],"prefix":"10.1021","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2593-8559","authenticated-orcid":true,"given":"Andrew M.","family":"Thompson","sequence":"first","affiliation":[{"name":"The University of Auckland , , Private Bag 92019, ,","place":["Auckland, New Zealand, 1142"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick D.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"The University of Auckland , , Private Bag 92019, ,","place":["Auckland, New Zealand, 1142"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Marshall","sequence":"additional","affiliation":[{"name":"The University of Auckland , , Private Bag 92019, ,","place":["Auckland, New Zealand, 1142"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Blaser","sequence":"additional","affiliation":[{"name":"The University of Auckland , , Private Bag 92019, ,","place":["Auckland, New Zealand, 1142"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Yardley","sequence":"additional","affiliation":[{"name":"London School of Hygiene & Tropical Medicine , , Keppel Street , ,","place":["London, United Kingdom, WC1E 7HT"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Maes","sequence":"additional","affiliation":[{"name":"University of Antwerp , , Universiteitsplein 1 , ,","place":["Antwerp, Belgium, B-2610"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Gupta","sequence":"additional","affiliation":[{"name":"CSIR-Central Drug Research Institute , , ,","place":["Lucknow, India, 226031"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Launay","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative , 15 Chemin Louis Dunant , ,","place":["Geneva, Switzerland, 1202"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Braillard","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative , 15 Chemin Louis Dunant , ,","place":["Geneva, Switzerland, 1202"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chatelain","sequence":"additional","affiliation":[{"name":"Drugs for Neglected Diseases initiative , 15 Chemin Louis Dunant , ,","place":["Geneva, Switzerland, 1202"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojie","family":"Wan","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago , , 833 South Wood Street , , ,","place":["Chicago, Illinois, United States, 60612"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott G.","family":"Franzblau","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago , , 833 South Wood Street , , ,","place":["Chicago, Illinois, United States, 60612"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenkun","family":"Ma","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development , 40 Wall Street , , ,","place":["New York, New York, United States, 10005"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Global Alliance for TB Drug Development , 40 Wall Street , , ,","place":["New York, New York, United States, 10005"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7997-1843","authenticated-orcid":true,"given":"William A.","family":"Denny","sequence":"additional","affiliation":[{"name":"The University of Auckland , , Private Bag 92019, ,","place":["Auckland, New Zealand, 1142"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2018,2,20]]},"reference":[{"key":"2026090218213094300_cit1","unstructured":"Leishmaniasis. World Health Organization: Geneva, 2017. http:\/\/www.who.int\/mediacentre\/factsheets\/fs375\/en\/ (accessed June 22, 2017)."},{"issue":"3","key":"2026090218213094300_cit2","doi-asserted-by":"publisher","first-page":"e31612","DOI":"10.5812\/pedinfect.31612","article-title":"Visceral leishmaniasis: An update\nand literature review","volume":"4","author":"Karimi","year":"2016","journal-title":"Archives of Pediatric\nInfectious Diseases"},{"key":"2026090218213094300_cit3","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/j.1469-0691.2011.03635.x","article-title":"Leishmaniasis impact\nand treatment access","volume":"17","author":"den Boer","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"2026090218213094300_cit4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1186\/s13071-016-1743-7","article-title":"A review\nof visceral leishmaniasis\nduring the conflict in South Sudan and the consequences for East African\ncountries","volume":"9","author":"Al-Salem","year":"2016","journal-title":"Parasites Vectors"},{"issue":"3","key":"2026090218213094300_cit5","doi-asserted-by":"publisher","first-page":"e0005231","DOI":"10.1371\/journal.pntd.0005231","article-title":"Visceral leishmaniasis\nin Somalia:\nA review of epidemiology and access to care","volume":"11","author":"Sunyoto","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"2026090218213094300_cit6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s40261-016-0481-0","article-title":"Safety and effectiveness of sodium\nstibogluconate and paromomycin combination for the treatment of visceral\nleishmaniasis in Eastern Africa: Results from a pharmacovigilance\nprogramme","volume":"37","author":"Kimutai","year":"2017","journal-title":"Clin. Drug Invest."},{"issue":"9","key":"2026090218213094300_cit7","doi-asserted-by":"publisher","first-page":"e0004880","DOI":"10.1371\/journal.pntd.0004880","article-title":"Efficacy and\nsafety of AmBisome in combination with sodium stibogluconate or miltefosine\nand miltefosine monotherapy for African visceral leishmaniasis: Phase\nII randomized trial","volume":"10","author":"Wasunna","year":"2016","journal-title":"PLoS Neglected Trop. Dis."},{"key":"2026090218213094300_cit8","unstructured":"Fexinidazole\/Miltefosine\nCombination (VL). DNDi, 2016. https:\/\/www.dndi.org\/diseases-projects\/portfolio\/completed-projects\/fexinidazole-vl\/ (accessed June 22, 2017)."},{"key":"2026090218213094300_cit9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bmc.2013.11.048","article-title":"Natural\nproduct based leads to fight against leishmaniasis","volume":"22","author":"Singh","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"2026090218213094300_cit10","unstructured":"Target\nProduct Profile for Visceral Leishmaniasis. DNDi, 2017. https:\/\/www.dndi.org\/diseases-projects\/leishmaniasis\/tpp-vl\/ (accessed December 7, 2017)."},{"key":"2026090218213094300_cit11","doi-asserted-by":"publisher","first-page":"11305","DOI":"10.1021\/cr500365f","article-title":"Recent developments in drug discovery\nfor leishmaniasis and human African trypanosomiasis","volume":"114","author":"Nagle","year":"2014","journal-title":"Chem. Rev."},{"key":"2026090218213094300_cit12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrmicro.2016.193","article-title":"Anti-trypanosomatid drug discovery:\nan ongoing challenge and a continuing need","volume":"15","author":"Field","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"2026090218213094300_cit13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1017\/S003118201300142X","article-title":"Screening strategies to identify new chemical diversity\nfor drug development to treat kinetoplastid infections","volume":"141","author":"Don","year":"2014","journal-title":"Parasitology"},{"key":"2026090218213094300_cit14","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/febs.13601","article-title":"Leishmania hijacking of the macrophage\nintracellular compartments","volume":"283","author":"Lie\u0301vin-Le Moal","year":"2016","journal-title":"FEBS J."},{"key":"2026090218213094300_cit15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2174\/1566524043360069","article-title":"Surface\ndeterminants of Leishmania parasites and their role\nin infectivity in the mammalian host","volume":"4","author":"Naderer","year":"2004","journal-title":"Curr.\nMol. Med."},{"key":"2026090218213094300_cit16","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nrd4683","article-title":"Hit and lead criteria in drug discovery\nfor infectious diseases of the developing world","volume":"14","author":"Katsuno","year":"2015","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2026090218213094300_cit17","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1039\/c4md00011k","article-title":"The role of\nmodern drug discovery in the fight against neglected and tropical\ndiseases","volume":"5","author":"Burrows","year":"2014","journal-title":"MedChemComm"},{"key":"2026090218213094300_cit18","doi-asserted-by":"publisher","first-page":"9615","DOI":"10.1021\/acs.jmedchem.5b01456","article-title":"Novel amino-pyrazole ureas with potent\nin vitro and in vivo antileishmanial activity","volume":"58","author":"Mowbray","year":"2015","journal-title":"J. Med. Chem."},{"key":"2026090218213094300_cit19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment\nof leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"key":"2026090218213094300_cit20","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.4155\/fmc.11.90","article-title":"Nitroimidazoles for the treatment of TB: past, present\nand future","volume":"3","author":"Mukherjee","year":"2011","journal-title":"Future Med. Chem."},{"key":"2026090218213094300_cit21","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1128\/AAC.06125-11","article-title":"Phase II\ndose-ranging trial of the\nearly bactericidal activity of PA-824","volume":"56","author":"Diacon","year":"2012","journal-title":"Antimicrob.\nAgents Chemother."},{"issue":"Suppl. 1","key":"2026090218213094300_cit22","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.5588\/ijtld.16.0069","article-title":"TB Alliance regimen development for\nmultidrug-resistant tuberculosis","volume":"20","author":"Murray","year":"2016","journal-title":"International\nJournal of Tuberculosis and Lung Disease"},{"key":"2026090218213094300_cit23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1128\/AAC.03823-14","article-title":"In vitro and in vivo activities of the\nnitroimidazole TBA-354 against Mycobacterium tuberculosis","volume":"59","author":"Upton","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090218213094300_cit24","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1021\/acs.jmedchem.7b00034","article-title":"7-Substituted 2-nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: novel antitubercular agents lead to a new\npreclinical candidate for visceral leishmaniasis","volume":"60","author":"Thompson","year":"2017","journal-title":"J. Med. Chem."},{"key":"2026090218213094300_cit25","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1021\/acs.jmedchem.5b01699","article-title":"Repositioning antitubercular\n6-nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for\nneglected tropical diseases: structure-activity studies on a preclinical\ncandidate for visceral leishmaniasis","volume":"59","author":"Thompson","year":"2016","journal-title":"J. Med.\nChem."},{"key":"2026090218213094300_cit26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/jac\/dku422","article-title":"Nitroimidazo-oxazole\ncompound DNDI-VL-2098: an orally effective preclinical drug candidate\nfor the treatment of visceral leishmaniasis","volume":"70","author":"Gupta","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"11","key":"2026090218213094300_cit27","doi-asserted-by":"publisher","first-page":"e1005971","DOI":"10.1371\/journal.ppat.1005971","article-title":"Activation\nof bicyclic nitro-drugs by a novel nitroreductase (NTR2) in Leishmania","volume":"12","author":"Wyllie","year":"2016","journal-title":"PLoS Pathog."},{"key":"2026090218213094300_cit28","doi-asserted-by":"publisher","first-page":"e09744","DOI":"10.7554\/eLife.09744","article-title":"The anti-tubercular drug delamanid\nas a potential oral treatment for visceral leishmaniasis","volume":"5","author":"Patterson","year":"2016","journal-title":"eLife"},{"key":"2026090218213094300_cit29","unstructured":"Thompson, A. M.; Denny, W. A.; Blaser, A.; Ma, Z.\n          Nitroimidazooxazine and Nitroimidazooxazole\nAnalogues and Their Uses. Patent WO 2011\/014776 A1,\n2011, and U.S. Patent 8293734 B2, 2012."},{"key":"2026090218213094300_cit30","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1016\/j.bmcl.2015.07.084","article-title":"Biarylmethoxy 2-nitroimidazooxazine\nantituberculosis agents: Effects of proximal ring substitution and\nlinker reversal on metabolism and efficacy","volume":"25","author":"Thompson","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090218213094300_cit31","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1016\/j.bmcl.2008.03.011","article-title":"Synthesis\nand antitubercular\nactivity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues\nof PA-824","volume":"18","author":"Li","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090218213094300_cit32","unstructured":"Baker, W. R.; Shaopei, C.; Keeler, E. L.\n          Nitro-[2,1-b]imidazopyran Compounds\nand Antibacterial Uses Thereof. U.S. Patent 6087358, 2000."},{"key":"2026090218213094300_cit33","unstructured":"Hirata, M.; Fujimoto, R.; Mikami, M.\n          Preparation of\n2-Methylglycidyl Ethers from 3-Halogeno-2-methyl-1,2-propanediols\nor 2-Methylepihalohydrins. Patent JP 2007297330, 2007."},{"key":"2026090218213094300_cit34","doi-asserted-by":"publisher","first-page":"8594","DOI":"10.1002\/chem.201403255","article-title":"Synthesis of cyclic alkenylsiloxanes\nby semihydrogenation:\na stereospecific route to (Z)-alkenyl polyenes","volume":"20","author":"Elbert","year":"2014","journal-title":"Chem. - Eur. J."},{"key":"2026090218213094300_cit35","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1128\/AAC.00106-09","article-title":"Safety,\ntolerability, and pharmacokinetics of PA-824 in healthy subjects","volume":"53","author":"Ginsberg","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090218213094300_cit36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.bmcl.2017.10.067","article-title":"Assessment of a\npretomanid analogue library for African trypanosomiasis: Hit-to-lead\nstudies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides","volume":"28","author":"Thompson","year":"2018","journal-title":"Bioorg.\nMed. Chem. Lett."},{"key":"2026090218213094300_cit37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1742-4658.2011.08404.x","article-title":"Substrate specificity of the deazaflavin-dependent\nnitroreductase from Mycobacterium tuberculosis responsible\nfor the bioreductive activation of bicyclic nitroimidazoles","volume":"279","author":"Gurumurthy","year":"2012","journal-title":"FEBS J."},{"key":"2026090218213094300_cit38","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1128\/AAC.00722-13","article-title":"The R enantiomer\nof the antitubercular drug PA-824 as a potential oral treatment for\nvisceral leishmaniasis","volume":"57","author":"Patterson","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090218213094300_cit39","doi-asserted-by":"publisher","first-page":"8421","DOI":"10.1021\/jm101288t","article-title":"Synthesis\nand structure-activity relationships of aza- and diazabiphenyl analogues\nof the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"53","author":"Kmentova","year":"2010","journal-title":"J. Med. Chem."},{"key":"2026090218213094300_cit40","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1021\/jm801087e","article-title":"Synthesis, reduction potentials,\nand antitubercular activity of ring A\/B analogues of the bioreductive\ndrug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"52","author":"Thompson","year":"2009","journal-title":"J. Med. Chem."},{"key":"2026090218213094300_cit41","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1021\/jm000144o","article-title":"The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin\ndisplays high lipophilicity, improved human blood stability, and potent\nanticancer activity","volume":"43","author":"Bom","year":"2000","journal-title":"J. Med. Chem."},{"key":"2026090218213094300_cit42","doi-asserted-by":"publisher","first-page":"6563","DOI":"10.1021\/jm200377r","article-title":"Synthesis and structure-activity\nrelationships of varied\nether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"54","author":"Thompson","year":"2011","journal-title":"J. Med. Chem."},{"key":"2026090218213094300_cit43","unstructured":"Alberati-Giani, D.; Jolidon, S.; Narquizian, R.; Nettekoven, M. H.; Norcross, R. D.; Pinard, E.; Stalder, H.\n          Preparation\nof 1-(2-Aminobenzoyl)-piperazine Derivatives as Glycine Transporter\n1 (GlyT-1) Inhibitors for Treating Psychoses. Patent WO 2005023260\nA1, 2005."},{"key":"2026090218213094300_cit44","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1177\/1087057115569155","article-title":"Repurposing of the open access malaria box for kinetoplastid\ndiseases identifies novel active scaffolds against trypanosomatids","volume":"20","author":"Kaiser","year":"2015","journal-title":"J. Biomol. Screening"},{"issue":"5","key":"2026090218213094300_cit45","doi-asserted-by":"publisher","first-page":"e675","DOI":"10.1371\/journal.pntd.0000675","article-title":"Antileishmanial\nhigh-throughput drug screening reveals\ndrug candidates with new scaffolds","volume":"4","author":"Siqueira-Neto","year":"2010","journal-title":"PLoS Neglected\nTrop. Dis."},{"key":"2026090218213094300_cit46","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1021\/jm501608q","article-title":"Synthesis\nand structure-activity relationships for extended side chain analogues\nof the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"58","author":"Palmer","year":"2015","journal-title":"J. Med. Chem."},{"key":"2026090218213094300_cit47","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1021\/jm901207n","article-title":"Synthesis and structure-activity studies of biphenyl\nanalogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"53","author":"Palmer","year":"2010","journal-title":"J. Med. Chem."},{"key":"2026090218213094300_cit48","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1021\/jm2012276","article-title":"Structure-activity\nrelationships for amide-, carbamate-, and urea-linked analogues of\nthe tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"55","author":"Blaser","year":"2012","journal-title":"J. Med. Chem."},{"key":"2026090218213094300_cit49","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1021\/jm901378u","article-title":"Synthesis and structure-activity relationships of antitubercular\n2-nitroimidazooxazines bearing heterocyclic side chains","volume":"53","author":"Sutherland","year":"2010","journal-title":"J. Med. Chem."},{"key":"2026090218213094300_cit50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejpb.2016.02.002","article-title":"Effects of gastric pH on oral drug\nabsorption: In vitro assessment using a dissolution\/permeation system\nreflecting the gastric dissolution process","volume":"101","author":"Kataoka","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2026090218213094300_cit51","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.parint.2016.10.020","article-title":"Imaging visceral leishmaniasis in\nreal time with golden hamster model:\nMonitoring the parasite burden and hamster transcripts to further\ncharacterize the immunological responses of the host","volume":"66","author":"Rouault","year":"2017","journal-title":"Parasitol. Int."},{"key":"2026090218213094300_cit52","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/bjp.2008.267","article-title":"Predicting QT prolongation\nin humans during early drug development using hERG inhibition and\nan anaesthetized guinea-pig model","volume":"154","author":"Yao","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"2026090218213094300_cit53","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1371\/journal.pntd.0000440","article-title":"Advancing drug innovation\nfor neglected diseases -\ncriteria for lead progression","volume":"3","author":"Nwaka","year":"2009","journal-title":"PLoS Neglected\nTrop. Dis."},{"key":"2026090218213094300_cit54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijpddr.2012.01.003","article-title":"Visceral\nleishmaniasis treatment: What do we have, what do we need and how\nto deliver it?","volume":"2","author":"Freitas-Junior","year":"2012","journal-title":"Int. J. Parasitol.: Drugs Drug\nResist."},{"key":"2026090218213094300_cit55","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/mutage\/ges015","article-title":"Genotoxicity profile of fexinidazole\n- a drug candidate in clinical development for human African trypanomiasis\n(sleeping sickness)","volume":"27","author":"Tweats","year":"2012","journal-title":"Mutagenesis"},{"key":"2026090218213094300_cit56","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/ejoc.201301363","article-title":"Total synthesis of\n(\u2212)-isoamericanin A and (+)-isoamericanol\nA","volume":"2014","author":"Pilkington","year":"2014","journal-title":"Eur. J. Org. Chem."},{"key":"2026090218213094300_cit57","doi-asserted-by":"publisher","first-page":"7305","DOI":"10.1021\/jm049006f","article-title":"Synthesis\nand biological activity of anticancer ether lipids that are specifically\nreleased by phospholipase A2 in tumor tissue","volume":"48","author":"Andresen","year":"2005","journal-title":"J. Med. Chem."},{"key":"2026090218213094300_cit58","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.pt.2014.04.003","article-title":"Nitro drugs for the treatment of trypanosomatid diseases:\npast, present, and future prospects","volume":"30","author":"Patterson","year":"2014","journal-title":"Trends\nParasitol."},{"key":"2026090218213094300_cit59","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1128\/AAC.49.4.1447-1454.2005","article-title":"In vitro and in vivo activities of macrolide derivatives\nagainst Mycobacterium tuberculosis","volume":"49","author":"Falzari","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090218213094300_cit60","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1128\/AAC.00055-06","article-title":"Low-oxygen-recovery\nassay for high-throughput screening\nof compounds against nonreplicating Mycobacterium tuberculosis","volume":"51","author":"Cho","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090218213094300_cit61","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ejps.2014.09.006","article-title":"In vitro metabolism,\ndisposition, preclinical pharmacokinetics and prediction of human\npharmacokinetics of DNDI-VL-2098, a potential oral treatment for Visceral\nLeishmaniasis","volume":"65","author":"Mukkavilli","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"2026090218213094300_cit63","doi-asserted-by":"publisher","first-page":"e0005620","DOI":"10.1371\/journal.pntd.0005620","article-title":"Combined treatment of miltefosine\nand paromomycin delays the onset of experimental drug resistance in Leishmania infantum","volume":"11","author":"Hendrickx","year":"2017","journal-title":"PLoS Neglected\nTrop. Dis."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.7b01581","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/61\/6\/2329\/67034410\/acs.jmedchem.7b01581.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/61\/6\/2329\/67034410\/acs.jmedchem.7b01581.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:21:46Z","timestamp":1788387706000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/61\/6\/2329\/696609\/Development-of-6R-2-Nitro-6-4-trifluoromethoxy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,20]]},"references-count":62,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,2,20]]},"published-print":{"date-parts":[[2018,3,22]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.7b01581","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,20]]}}}